tirzepatide vs semaglutide weight loss speed In adults with obesity but not diabetes, leads to significantly greater than over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Semaglutide vs. Tirzepatide for Obesity

Additionally, patients with inflammatory bowel disease, severe gastroesophageal reflux disease, or other significant gastrointestinal disorders should be monitored closely if treatment is initiated, as the gastrointestinal effects of semaglutide may worsen their underlying condition

doi: 10.3389/fendo.2023.1226687 Received 22 May 2023 Accepted 01 August 2023 Published 16 August 2023 Volume 14 - 2023 Edited by Iveta Yotova, Medical University of Vienna, Austria Reviewed by Michele Da Broi, University of Sao Paulo, Brazil

Building your GLP-1 qualification strategy by BMI range Based on everything covered above, here is a practical strategy guide organized by your current BMI range

Patients starting tirzepatide therapy through PlexusDx receive detailed rotation charts to make site selection automatic and effortless